Research report
Limiting dilution analysis of virus-specific memory B cells by an ELISPOT assay

https://doi.org/10.1016/S0022-1759(96)00146-9Get rights and content

Abstract

Many acute viral infections induce long-term, sometimes even life-long humoral immunity. To characterize this immune response, accurate quantitation of memory B cells and plasma cells is essential. Plasma cells can be quantitated directly ex vivo by virtue of their ability to spontaneously secrete antibody. Memory B cells on the other hand, do not spontaneously secrete antibody but require antigenic stimulation in order to proliferate and differentiate into antibody secreting cells (ASC). In this study, an ELISPOT-based limiting dilution assay (LDA) was developed for quantitating virus-specific B cell memory following acute lymphocytic choriomeningitis virus (LCMV) infection of adult mice. Antiviral memory B cell precursor (MBCp) frequencies were calculated from in vitro stimulated cultures using either a conventional ELISA-based LDA to measure accumulated virus-specific antibody in the culture medium or a new ELISPOT-based LDA that identifies the antibody-secreting daughter cells directly. In terms of sensitivity, the ELISPOT-based LDA and the ELISA-based LDA both calculated LCMV-specific MBCp frequencies to be approximately 12 × 104 spleen cells. However, compared to the 12 days of in vitro stimulation required to estimate MBCp frequencies by the ELISA-based LDA, the ELISPOT-based LDA required only 3–6 days of stimulation to quantitate MBCp frequencies. If cell division was blocked by γ-irradiation or treatment with mitomycin C, the MBCp frequency dropped below detection (< 1MBCp106 cells), indicating that virus-specific B cells quantitated by this assay must both proliferate and differentiate into antibody secreting cells in order to be detected. Naive, uninfected mice did not have LCMV-specific memory B cells, demonstrating that only in vivo-generated antiviral B cells from LCMV-immune mice were detected by this assay. χ2 analysis of the ELISPOT-based LDA showed that the MBCp frequency data fit a linear regression model (p = 0.0137), indicating single-hit kinetics in which only one cell type was limiting. These results indicate that the ELISPOT-based LDA provides a rapid and statistically accurate method to quantitate virus-specific B cells.

References (27)

  • W.W. Bullock et al.

    In vitro initiated secondary anti-hapten response. II. Increasing cell avidity for antigen

    J. Exp. Med.

    (1970)
  • J.A. Byrne et al.

    Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus in vivo

    J. Virol.

    (1984)
  • D.M. Hilbert et al.

    T cell derived IL-6 is differentially required for antigen-specific antibody secretion by primary and secondary B cells

    J. Immunol.

    (1989)
  • Cited by (86)

    • Scalable production and immunogenicity of a cholera conjugate vaccine

      2021, Vaccine
      Citation Excerpt :

      Nitrocellulose bottom plates (MAHAS4510, Millipore) were coated with OSP:BSA (100 ng/well), or keyhole limpet hemocyanin (KLH; Pierce Biotechnology) (2.5 μg/ml, negative control) or goat anti-mouse IgG (Southern Biotech) [30,31,34]. We assessed memory B cell responses after the final round of immunization as previously described [30,31,34]. We used unstimulated samples as negative controls and subtracted responses to KLH as a control for the plate.

    • CD19-positive antibody-secreting cells provide immune memory

      2018, Blood Advances
      Citation Excerpt :

      Therefore, the potential secreted immunoglobulin contribution to humoral immunity of CD19+ ASCs is greater than CD19− ASCs based on frequency and tissue distribution. Long-lived immunity and the presence of high-affinity serum IgG antibodies specific for previously encountered antigens, like vaccine antigens, was described as existing for decades independent of memory B cells3,17,40,41 and was thought to be contributed only by CD19− BM ASCs. Our work shows both CD19+ and negative ASCs also exist in the spleen and have similar capability as the BM ASCs to recognize vaccine antigens (Figure 3).

    • Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe

      2017, EBioMedicine
      Citation Excerpt :

      Exploratory immunological outcomes, only for cohort 3 of study 2, included assessment of memory B cells (MBC), specific for the OAg and its GMMA carrier, and of antibody secreting cells (plasmablasts) on PBMCs obtained at baseline and at 28 days after the third immunization (MBC) and at 7 days after the first immunization (plasmablasts). Assays were performed at GSK Vaccines, Siena, Italy, by ELISpot, following standard procedures (Slifka and Ahmed, 1996). Serum anti-S.

    • An optimized method for enumerating CNS derived memory B cells during viral-induced inflammation

      2017, Journal of Neuroscience Methods
      Citation Excerpt :

      Culture conditions designed to quantify virus-specific Bmem have largely been optimized using cells derived from lymphoid tissue and rely on various in vitro stimulation strategies to convert Bmem into ASC, which are then measured by ELISPOT in a separate plate. In vitro this process requires proliferation and thus prolonged stimulation more than 24 h, the minimum time required to trigger division by Bmem (Slifka and Ahmed, 1996b). For instance, following LCMV infection maximal virus-specific Bmem conversion into ASC was initially achieved by stimulating splenocytes from LCMV infected mice at serial dilutions with irradiated LCMV infected carrier splenocytes as a source of viral antigen for 6 days p.i (Slifka and Ahmed, 1996b).

    View all citing articles on Scopus
    View full text